Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Talking Therapeutics

Douglass Jennings
Talking Therapeutics
07/19/2024
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.
In this installment of Talking...
07/19/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
06/24/2024
In this installment of Talking Therapeutics, Dr Jennings reviews a study demonstrating that racial bias in medicine may prevent positive treatment outcomes for Black patients with hypertension and heart failure with a reduced ejection...
In this installment of Talking Therapeutics, Dr Jennings reviews a study demonstrating that racial bias in medicine may prevent positive treatment outcomes for Black patients with hypertension and heart failure with a reduced ejection...
In this installment of Talking...
06/24/2024
Pharmacy Learning Network
Douglas Jennings
Talking Therapeutics
06/06/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.
In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.
In this week's installment of...
06/06/2024
Pharmacy Learning Network
Douglas Jennings
Talking Therapeutics
05/24/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings explores a new paper outlining the potential benefit of statins on key outcomes in patients with heart failure with preserved ejection fraction (HFpEF).
In this installment of Talking Therapeutics, Dr Jennings explores a new paper outlining the potential benefit of statins on key outcomes in patients with heart failure with preserved ejection fraction (HFpEF).
In this installment of Talking...
05/24/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
05/09/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings explores another potentially dangerous direct-acting oral anticoagulant (DOAC) combination based on a recent study.
In this installment of Talking Therapeutics, Dr Jennings explores another potentially dangerous direct-acting oral anticoagulant (DOAC) combination based on a recent study.
In this installment of Talking...
05/09/2024
Pharmacy Learning Network
Talking Therapeutics
04/25/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings analyzes recent study findings determining efficacy of dapagliflozin in patients with acute heart failure.
In this installment of Talking Therapeutics, Dr Jennings analyzes recent study findings determining efficacy of dapagliflozin in patients with acute heart failure.
In this installment of Talking...
04/25/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
04/09/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings discusses the risks associated with combining selective serotonin inhibitors (SSRIs) and blood thinners.
In this installment of Talking Therapeutics, Dr Jennings discusses the risks associated with combining selective serotonin inhibitors (SSRIs) and blood thinners.
In this installment of Talking...
04/09/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
04/08/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings examines the interactions between amiodarone and rivaroxaban for patients under prescription, outlining crucial considerations for prescribers when administering these medications to...
In this installment of Talking Therapeutics, Dr Jennings examines the interactions between amiodarone and rivaroxaban for patients under prescription, outlining crucial considerations for prescribers when administering these medications to...
In this installment of Talking...
04/08/2024
Pharmacy Learning Network
Douglass Jennings
Talking Therapeutics
03/14/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluated a simplified calcium administration plan to prevent hypertensive-related pregnancy complications.
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluated a simplified calcium administration plan to prevent hypertensive-related pregnancy complications.
In this installment of Talking...
03/14/2024
Pharmacy Learning Network
Douglass Jennings
Talking Therapeutics
03/12/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, Dr Jennings reviews triptans and their impact on myocardial infarction and cerebrovascular accidents.
In this installment of Talking Therapeutics, Dr Jennings reviews triptans and their impact on myocardial infarction and cerebrovascular accidents.
In this installment of Talking...
03/12/2024
Pharmacy Learning Network

Advertisement

Advertisement